Continuous Positive Airway Pressure (CPAP) Devices Market Size, Share, and Growth Forecast 2026 - 2033

The global Continuous Positive Airway Pressure (CPAP) Devices market size is expected to reach US$ 3.6 billion in 2026 and is projected to reach US$ 5.5 billion by 2033, growing at a CAGR of 6.2% between 2026 and 2033.

Rising prevalence of sleep-disordered breathing, especially obstructive sleep apnea (OSA), combined with increasing diagnosis rates and growing awareness of cardiovascular and metabolic risks, is accelerating demand for CPAP therapy worldwide. Aging populations, higher obesity rates, and lifestyle-related risk factors have led to a larger pool of patients requiring long-term respiratory support, while clinical evidence from randomized trials in COVID 19–related hypoxemic respiratory failure has reinforced the role of noninvasive ventilation strategies such as CPAP in acute and chronic care. Parallel advances in device miniaturization, comfort-focused mask designs, and integrated telemonitoring functionalities are improving adherence and outcomes, supporting sustained market expansion through the forecast period.

• North America remains the leading CPAP devices region, supported by high OSA and COPD diagnosis rates, strong reimbursement, and robust sleep medicine infrastructure, with the U.S. anchoring demand across home care and hospital segments.
• Asia Pacific is the fastest-growing regional market, driven by rising awareness of sleep-disordered breathing, expanding healthcare access in China, India, and ASEAN, and cost-effective regional manufacturing that supports both domestic consumption and exports.
• Among product categories, CPAP Machines dominate global revenue, reflecting their central role in therapy initiation and long replacement cycles, with advanced APAP and BiPAP systems gaining share due to enhanced comfort and tailored respiratory support.
• On the application front, COPD leads current usage, while OSA is the fastest-growing segment as HSAT adoption, obesity trends, and cardiometabolic risk awareness drive more patients into long-term CPAP therapy pathways worldwide.
• A key market opportunity lies in connected, AI-enabled CPAP ecosystems that combine smart devices, remote monitoring, and analytics, enabling personalized therapy optimization, improved adherence, and recurring revenues from software, services, and consumables.

Market Growth Drivers

Growing burden of sleep-disordered breathing and cardiometabolic risks

The primary growth driver for the global CPAP devices market is the rising burden of sleep-disordered breathing, particularly OSA, which is strongly associated with hypertension, cardiovascular disease, stroke, and type 2 diabetes. Large epidemiological studies suggest that moderate to severe OSA may affect close to 1 billion adults globally, yet diagnosis rates remain comparatively low, creating a substantial treatment gap that favors sustained CPAP adoption. Clinical evidence indicates that effective CPAP therapy can improve daytime sleepiness, blood pressure control, and overall quality of life, encouraging guideline recommendations to prioritize CPAP as first-line therapy in moderate to severe OSA. As payers and healthcare systems recognize the long-term cost savings from preventing cardiovascular events, reimbursement support for CPAP devices, masks, and accessories is strengthening in major markets, further reinforcing demand.

Expanded use of CPAP in acute respiratory care and post-COVID protocols

A second major driver is the broadened role of CPAP beyond chronic sleep therapy into acute respiratory support, particularly highlighted during the COVID-19 pandemic. Randomized clinical trials involving more than 1,200 hospitalized adults with COVID-19–related acute hypoxemic respiratory failure showed that an initial CPAP strategy significantly reduced the composite risk of tracheostomy or mortality within 30 days compared with conventional oxygen therapy, prompting wider adoption of noninvasive ventilation in intensive and intermediate care settings. Subsequent real-world evaluations demonstrated that helmet and mask-based CPAP could help mitigate ICU bed shortages and reduce the need for invasive mechanical ventilation when appropriately monitored. This experience has led many hospitals to permanently expand their noninvasive respiratory care capacity, supporting continued procurement of CPAP machines, circuits, and related accessories as part of respiratory care and emergency preparedness pathways.

Market Restraints

Adherence challenges and patient discomfort

Despite proven efficacy, CPAP therapy faces persistent adherence challenges driven by mask discomfort, skin irritation, nasal congestion, and intolerance to continuous positive pressure. Published adherence data often show that a significant subset of patients use CPAP for fewer than 4 hours per night, below recommended thresholds for optimal clinical benefit. Suboptimal adherence reduces real-world effectiveness, undermines payer confidence, and can lead to therapy discontinuation or switching to alternative modalities such as mandibular advancement devices or upper-airway surgery, thereby restraining overall market potential.

Cost pressures and reimbursement variability

Another key barrier is the variability in reimbursement and out-of-pocket costs across regions, especially in low- and middle-income countries where insurance coverage for sleep diagnostics and long-term CPAP therapy remains limited. In markets with fragmented reimbursement, patients may bear the upfront cost of CPAP machines, masks, and replacement components, which can discourage device initiation or timely replacement. Competitive pricing pressures, tender-based hospital procurement, and cost-containment initiatives by public payers can also compress margins for manufacturers, limiting investment capacity in innovation and patient support programs in price-sensitive regions.

Market Opportunities

Rapid growth of home-based sleep diagnosis and therapy models

A major opportunity for CPAP device manufacturers is the rapid shift toward home sleep apnea testing (HSAT) and remote management models, which lower diagnostic barriers and accelerate treatment initiation. Recent analyses show the global home sleep apnea test market growing at CAGRs in the mid-single to low-double digits, driven by portable diagnostic devices, telemedicine, and payer support for out-of-lab testing. As more patients receive OSA diagnoses via home testing pathways, the addressable base for home CPAP equipment, cloud-connected devices, and subscription-based mask and filter replenishment programs expands significantly. Integration of CPAP platforms with digital health ecosystems, mobile apps, and remote monitoring dashboards allows providers to optimize therapy settings, monitor adherence, and intervene early, creating recurring revenue opportunities for device manufacturers and durable equipment providers.

Integration of smart, AI-enabled, and connected CPAP ecosystems

Another powerful opportunity lies in developing smart CPAP systems that leverage advanced sensors, algorithms, and connectivity to deliver personalized therapy. Emerging respiratory care platforms increasingly integrate features such as auto-adjusting pressure algorithms, leak detection, sleep staging estimation, and wireless data transmission to clinician portals or patient apps. Manufacturers are exploring artificial intelligence and machine learning tools to analyze longitudinal breathing patterns, predict adherence risks, and automatically fine-tune therapy parameters, thereby improving comfort and outcomes. Alongside this, integration with hospital information systems and cloud-based patient monitoring platforms like the connected respiratory and patient monitoring solutions spun out from large medtech players creates an ecosystem opportunity for recurring software, analytics, and service revenues tied to CPAP devices deployed in both hospital and home settings.

Product Type Analysis

Within product type, CPAP Machines are expected to remain the leading segment, accounting for approximately 62% of the global CPAP devices market in 2025, ahead of masks and accessories. This dominance reflects the central role of the device hardware as the primary capital component in both sleep laboratories and home therapy, with replacement cycles typically every 5–7 years in many reimbursed markets. Among CPAP machines, auto-adjusting CPAP (APAP) and bi-level (BiPAP) systems are gaining share because they dynamically adapt pressure, improve comfort, and better support patients with comorbid respiratory conditions, particularly COPD and obesity hypoventilation syndrome. As clinical guidelines increasingly emphasize individualized titration and adherence, demand for advanced, feature-rich CPAP systems that incorporate connectivity, data logging, and noise reduction is expected to bolster machine revenue leadership over the forecast period.

Application Analysis

In application terms, Chronic Obstructive Pulmonary Disease (COPD) represents the leading segment, with an estimated 43% market share in 2025, driven by the large and growing global COPD patient base and the use of noninvasive ventilation in acute exacerbations and chronic respiratory failure. Bi-level CPAP devices are widely used to support COPD patients by improving ventilation, reducing the work of breathing, and stabilizing gas exchange, especially in hospital and high-dependency settings. However, OSA is expected to be the fastest-growing application segment through 2033, supported by rising diagnoses via HSAT, obesity trends, and increasing recognition of OSA’s cardiometabolic burden. As guidelines and payer policies expand coverage for OSA screening and treatment, the OSA segment will contribute strongly to incremental CPAP device and accessory volumes across both developed and emerging markets.

End User Analysis

Among end users, Home Care Settings are projected to command the largest share of the CPAP devices market by 2025, with an estimated contribution of about 55%, outpacing hospitals and clinics as care delivery shifts toward decentralized and patient-centric models. The combination of HSAT, teleconsultations, and mail-order delivery of CPAP equipment has made home initiation of therapy more convenient and cost-effective for patients and payers, particularly in North America and parts of Europe. At the same time, cloud-connected devices enable clinicians and durable medical equipment providers to remotely monitor adherence and efficacy, reducing the need for frequent in-person visits and supporting scalable chronic care management. As aging populations and chronic respiratory disease prevalence grow, home-based noninvasive ventilation and sleep therapy are expected to remain the primary setting for CPAP device utilization and replacement.

North America Continuous Positive Airway Pressure (CPAP) Devices Market Trends and Insights

North America is the leading regional market for CPAP devices, accounting for around 36% of global revenue in 2025, supported by high OSA awareness, advanced diagnostic infrastructure, and strong reimbursement frameworks in the U.S. and Canada. In the U.S., large insured populations and specialized sleep centers and accredited sleep laboratories underpin substantial installed bases of CPAP machines and home care setups. Medicare and commercial insurers increasingly reimburse HSAT and long-term CPAP therapy for diagnosed OSA, reinforcing sustained demand for devices, masks, and replacement accessories.

The regional innovation ecosystem is robust, with leading medtech companies integrating CPAP devices into broader connected respiratory and patient monitoring portfolios, including telemonitoring platforms and analytics solutions. Evidence from major COVID-19 clinical trials conducted in North American and European centers demonstrated the effectiveness of CPAP as part of noninvasive respiratory strategies, prompting hospitals to expand their stock of acute-care CPAP systems to build surge capacity. Regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) ensures rigorous safety and performance standards, while also shaping requirements for cybersecurity, data privacy, and software updates for connected CPAP systems.

Asia Pacific Continuous Positive Airway Pressure (CPAP) Devices Market Trends and Insights

The Asia Pacific region is expected to be the fastest-growing market for CPAP devices between 2025 and 2033, driven by expanding healthcare infrastructure, rising incomes, and greater recognition of sleep and respiratory disorders in China, Japan, India, and ASEAN countries. Urbanization, aging populations, and increasing obesity rates are contributing to a higher prevalence of OSA and COPD, yet diagnosis and treatment penetration remain relatively low, creating substantial headroom for growth as screening initiatives and specialist services expand. Governments and private providers are progressively investing in sleep laboratories, respiratory clinics, and home care services, which is likely to accelerate the adoption of CPAP machines and accessories.

Asia Pacific also benefits from strong manufacturing advantages, particularly in China and parts of ASEAN, where several regional players produce cost-competitive CPAP devices and components that support both domestic and export markets. Local production capabilities help reduce costs and improve supply resilience, which became especially relevant during pandemic-related supply chain disruptions. As telemedicine and digital health platforms proliferate, integration of CPAP therapy with remote monitoring and mobile applications is expected to gain momentum, particularly in technologically advanced markets like Japan and South Korea, further reinforcing the region’s high growth outlook.

The global CPAP devices market is moderately consolidated, with a mix of large multinational medtech companies and specialized respiratory care manufacturers competing across machines, masks, and accessories. Leading players differentiate through broad product portfolios, advanced auto-titrating and bi-level systems, patient-friendly mask designs, and integrated telemonitoring platforms. Strategic priorities include investment in R&D for quieter, smarter, and more comfortable devices; expansion into high-growth emerging markets; and development of subscription and service-based business models for home care and cloud-connected respiratory monitoring. Partnerships with sleep laboratories, homecare providers, and digital health platforms are increasingly used to enhance data integration, adherence support, and long-term customer retention.

Key Market Developments

• In December 2025, SleepRes, Inc., a sleep technology company focused on reimagining therapy for sleep breathing disorders, announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Kricket PAP device, powered by Kairos Positive Airway Pressure (KPAP)™. The device was cleared for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. The SleepRes PAP system was intended for use in home, hospital/institutional, and sleep center settings.